These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24559446)

  • 1. Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer.
    Ferguson K; Yadav A; Morey S; Abdullah J; Hrysenko G; Eng JY; Sajjad M; Koury S; Rittenhouse-Olson K
    Future Oncol; 2014 Feb; 10(3):385-99. PubMed ID: 24559446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.
    Heimburg J; Yan J; Morey S; Glinskii OV; Huxley VH; Wild L; Klick R; Roy R; Glinsky VV; Rittenhouse-Olson K
    Neoplasia; 2006 Nov; 8(11):939-48. PubMed ID: 17132226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.
    Tati S; Fisk JC; Abdullah J; Karacosta L; Chrisikos T; Philbin P; Morey S; Ghazal D; Zazala F; Jessee J; Quataert S; Koury S; Moreno D; Eng JY; Glinsky VV; Glinskii OV; Sesay M; Gebhard AW; Birthare K; Olson JR; Rittenhouse-Olson K
    Neoplasia; 2017 Sep; 19(9):716-733. PubMed ID: 28830009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.
    Karacosta LG; Fisk JC; Jessee J; Tati S; Turner B; Ghazal D; Ludwig R; Johnson H; Adams J; Sajjad M; Koury S; Roy R; Olson JR; Rittenhouse-Olson K
    Transl Oncol; 2018 Apr; 11(2):450-466. PubMed ID: 29477636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jaa-f11: extending the life of mice with breast cancer.
    Rittenhouse-Olson K
    Expert Opin Biol Ther; 2007 Jul; 7(7):923-8. PubMed ID: 17665983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models.
    Ghazal D; Zalzala F; Fisk JC; Tati S; Karacosta LG; Morey S; Olson JR; Quataert S; Dy GK; Rittenhouse-Olson K
    Oncotarget; 2022 Oct; 13():1155-1164. PubMed ID: 36264086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy.
    Almogren A; Abdullah J; Ghapure K; Ferguson K; Glinsky VV; Rittenhouse-Olson K
    Front Biosci (Schol Ed); 2012 Jan; 4(3):840-63. PubMed ID: 22202095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.
    Heimburg-Molinaro J; Almogren A; Morey S; Glinskii OV; Roy R; Wilding GE; Cheng RP; Glinsky VV; Rittenhouse-Olson K
    Neoplasia; 2009 Aug; 11(8):780-92. PubMed ID: 19649208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen.
    Chaturvedi R; Heimburg J; Yan J; Koury S; Sajjad M; Abdel-Nabi HH; Rittenhouse-Olson K
    Appl Radiat Isot; 2008 Mar; 66(3):278-87. PubMed ID: 17890096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational screening of the human TF-glycome provides a structural definition for the specificity of anti-tumor antibody JAA-F11.
    Tessier MB; Grant OC; Heimburg-Molinaro J; Smith D; Jadey S; Gulick AM; Glushka J; Deutscher SL; Rittenhouse-Olson K; Woods RJ
    PLoS One; 2013; 8(1):e54874. PubMed ID: 23365681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.
    Behe M; Alt K; Deininger F; Bühler P; Wetterauer U; Weber WA; Elsässer-Beile U; Wolf P
    In Vivo; 2011; 25(1):55-9. PubMed ID: 21282735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
    Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
    J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.
    Fu M; Maresh EL; Helguera GF; Kiyohara M; Qin Y; Ashki N; Daniels-Wells TR; Aziz N; Gordon LK; Braun J; Elshimali Y; Soslow RA; Penichet ML; Goodglick L; Wadehra M
    Mol Cancer Ther; 2014 Apr; 13(4):902-15. PubMed ID: 24448822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum to "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis" [Neoplasia 19.9 (2017) 716-733].
    Tati S; Fisk JC; Abdullah J; Karacosta L; Chrisikos T; Philbin P; Morey S; Ghazal D; Zalzala F; Jessee J; Quataert S; Koury S; Moreno D; Eng JY; Glinsky VV; Glinskii OV; Sesay M; Gebhard AW; Birthare K; Olson JR; Rittenhouse-Olson K
    Neoplasia; 2018 Jan; 20(1):118. PubMed ID: 29277397
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.